Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) shares rose 7% on Thursday . The stock traded as high as $0.48 and last traded at $0.46. Approximately 764,392 shares were traded during trading, an increase of 12% from the average daily volume of 683,007 shares. The stock had previously closed at $0.43.

PLX has been the subject of several research analyst reports. HC Wainwright set a $5.00 target price on Protalix Biotherapeutics and gave the stock a “buy” rating in a research note on Friday, May 11th. Zacks Investment Research raised Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 12th.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The firm had revenue of $4.55 million during the quarter, compared to analyst estimates of $4.40 million. During the same period in the prior year, the company posted ($0.48) earnings per share.

A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. SG Americas Securities LLC bought a new stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 225,000 shares of the company’s stock, valued at approximately $121,000. SG Americas Securities LLC owned approximately 0.15% of Protalix Biotherapeutics as of its most recent SEC filing.

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with's FREE daily email newsletter.